Review of: "Lymphoma: Potential Viral Antagonism between HTLV-1 and JCV Associated with Increased Survival Time"

Xuan Jiang

Potential competing interests: No potential competing interests to declare.

In this article, the author explores the intriguing hypothesis of viral antagonism between HTLV-1 and JCV in lymphoma patients. Despite the topic's interest, the article falls short in presenting compelling evidence to substantiate this hypothesis. Several key points highlight the limitations:

1. Presently, no comprehensive studies conclusively demonstrate a direct association between JCV and lymphoma. JCV, a polyomavirus primarily linked to progressive multifocal leukoencephalopathy (PML), boasts high seroprevalence, infecting 70-90% of the global population. While drugs like rituximab for lymphoma can reactivate latently infected JCV, leading to PML, a direct link between JCV and lymphoma remains unsubstantiated. Additionally, there is no evidence supporting the co-infection of JCV and HTLV-1 in NHL cases.
2. In their discussion, Engels, E. A. et al. propose four potential explanations for reduced JCV antibody levels in NHL cases. However, there is no indication in their study that JCV acts as a protective agent against lymphoma. The possibilities mentioned are related to confounding factors, disease effects, treatment effects, and a potential etiological role for JCV in NHL.
3. The author relies on protein sequence alignment between JCV and HTLV-1 as evidence. However, the high E score and the limited coverage of a small region in both protein sequences indicate only a modest similarity. It's crucial to note that similarities in protein sequences don't necessarily translate to similar epitopes, as seen in antibodies against the spike proteins of various SARS-CoV-2 strains. Addressing such questions requires a more in-depth comparison of protein structures using in silico methods and modeling for antibody-protein interactions.

In conclusion, the article posits a hypothesis lacking robust evidence. The preliminary sequence alignment results are insufficient to support the hypothesis. A retrospective investigation based on a larger number of cases is required. Experimental evidence, particularly showcasing the cross-reactivity of antibodies, is imperative to validate any potential associations.